DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.28
−2.28%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +0.2%
- EBIT
- -1.7%
- EPS
- -1.4%
- Free cash flow
- -18.9%
- Operating cash flow
- -24.1%
Forward estimates
Based on analyst estimates
- Revenue
- +2191.2%
- EBITDA
- +16.9%
- EPS
- +19.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -1.0%
- EBIT
- -14.0%
- Net income
- -21.2%
- EPS
- -15.6%
- Free cash flow
- -16.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026